C-reactive protein (CRP) is an acute-phase response protein induced by interleukin 6 (IL-6) produced in liver cells, with normal reference value < 5 mg/L. The advancement of testing technology has improved the sensitivity and accuracy of CRP detection. Existing testing instruments can detect extremely low concentrations of CRP in serum samples, known as high-sensitivity C-reactive … Read more
The ADC field has gradually been pushed to market since 2000, and in recent years has surged in cancer treatment, leading to rapid development and fierce competition in this sector. To differentiate themselves, some companies are beginning to develop ADCs for non-oncology applications. Although the number of related ADCs is very small and most are … Read more
Progress in Myositis-Specific Antibody Research 1. Clinical Significance of Myositis Antibodies: Helps in IIM classification; predicts IIM progression; aids in predicting complications of IIM; assists in determining treatment plans for IIM. Myositis antibody spectrum 10-year survival rate observation: anti-SRP > anti-HMGCR > anti-Mi-2 > anti-NXP-2 > anti-SAE > anti-TIF1-Υ > anti-MDA5. 2. NXP-2 Antibody: ① … Read more
Follow us Click on the blue text above to follow us Testing Project Information Testing Item: Myositis Antibody Spectrum Testing for 19 Items (Mi-2, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, Ro-52, TIF1γ, MDA5, NXP2, HMGCR, SAE, OJ, KS, ZO, HA) Medical Advice Information Advice Code: JYJYK4055, Advice Name: Myositis Antibody Spectrum Testing Advice … Read more
CRP is an acute phase protein synthesized by liver cells in response to inflammatory stimuli such as microbial invasion or tissue damage. The acute phase response includes changes in the concentration of certain serum proteins during infection, inflammation, and trauma. These proteins, in addition to CRP, include serum amyloid A, fibrinogen, haptoglobin, α1-acid glycoprotein, ceruloplasmin, … Read more
▎This article is contributed by Ying’en Biotech (slightly edited) Since the first antibody-drug conjugate (ADC) was approved for the treatment of acute myeloid leukemia in 2000, after more than twenty years of exploration and development, 14 ADC drugs have been successfully approved for clinical treatment of tumors. In August 2022, the FDA announced the accelerated … Read more
Since 2000, the ADC field has gradually started to be pushed to market, and in recent years, it has emerged rapidly in the field of cancer treatment, leading to intense competition. To differentiate themselves, some companies are beginning to develop ADCs for non-oncology areas. Although the number of related ADCs is extremely limited and most … Read more